Screening tests serve as an early warning system, identifying potential cancers even before they present symptoms. At present, recommended screening tests are available for just five types of cancer – colorectal, lung (for those at risk), breast, cervical, and prostate. Unfortunately, many other cancers, including pancreatic and ovarian, often remain silent in the early stages, making them more likely to be diagnosed at a later stage.
The benefits of early detection cannot be overstated. When cancer is caught early, before it has a chance to spread, the five-year cancer-specific survival rate quadruples compared to late-stage diagnoses. Early detection is your first line of defense – make it count.
The TruCheck test does not detect all cancer types and not all cancer types can be detected in the blood. False negative and false positive results do occur.
Cancer does not discriminate; it is a disease that impacts many. In fact, over one-third of people will face a cancer diagnosis in their lifetime.
One of the most significant risk factors for cancer is age. As we grow older, the risk of developing cancer increases, particularly once we cross the age of 50. Adults over 50 are 13 times more likely to be diagnosed with cancer compared to their younger counterparts.
While it’s true that a family history of cancer can elevate risk levels, it’s crucial to note that genetics play a role in only 5% to 10% of cancer cases. Thus, an increase in cancer risk with age is a universal reality, irrespective of one’s family history.
Understanding these facts underlines the importance of regular health check-ups and screenings, especially as we age, to help in early detection and potentially successful treatment.
However, it is important to remember that the earlier a cancer is discovered, the higher the chances of successful treatment and survival. The principle is straightforward: the sooner you know, the sooner you can take action. This reaffirms the importance of proactive health monitoring and vigilance for early signs, thus maximising the chances of swift and effective intervention.
However, it’s more likely that an individual being screened for a specific type of cancer will be diagnosed with a different type of cancer entirely. This highlights the need for comprehensive and broader screening methods to supplement these specific tests, enhancing early detection for a range of cancers.
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
